Wednesday, April 24, 2019
How complex can the Tumor microenvironment be?
The authors of this review exhaustively detail the different tumor microenvironment (TME) regulatory pathways in classic Hodgkins Lymphoma tumors and identify some of the methods being used to get around them.
They include many of the standard of care therapies as well as some clinical trials that are underway.
The conclusion states that a more complete understanding of the TME is necessary to build biomarkers as well as effective therapies that will be able to treat the cancer cells, but also to treat the "educated" support cells that are enabling the TME itself.